Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Exchange Rate Effect (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Exchange Rate Effect for 16 consecutive years, with -$65000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Exchange Rate Effect rose 50.0% to -$65000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $86000.0, a 279.17% increase, with the full-year FY2025 number at $86000.0, up 279.17% from a year prior.
  • Exchange Rate Effect was -$65000.0 for Q4 2025 at Anika Therapeutics, up from -$302000.0 in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $345000.0 in Q2 2025 to a low of -$302000.0 in Q3 2025.
  • A 5-year average of $2800.0 and a median of -$13000.0 in 2022 define the central range for Exchange Rate Effect.
  • Peak YoY movement for Exchange Rate Effect: soared 850.0% in 2023, then tumbled 929.63% in 2024.
  • Anika Therapeutics' Exchange Rate Effect stood at $118000.0 in 2021, then tumbled by 158.47% to -$69000.0 in 2022, then surged by 210.14% to $76000.0 in 2023, then plummeted by 271.05% to -$130000.0 in 2024, then skyrocketed by 50.0% to -$65000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Exchange Rate Effect are -$65000.0 (Q4 2025), -$302000.0 (Q3 2025), and $345000.0 (Q2 2025).